About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Moderna to Showcase Extensive Infectious Disease Research at ESCMID 2025

CAMBRIDGE, MA / ACCESS Newswire / April 7, 2025 / Moderna, Inc. (NASDAQ: MRNA) today announced that the Company will present research across multiple infectious disease areas, including COVID-19, influenza, respiratory syncytial virus (RSV), cytomegalovirus (CMV), norovirus, and mpox, at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Vienna, Austria, from April 11-15, 2025.

Moderna will present twelve scientific presentations at the ESCMID 2025 Global Congress, including three oral presentations, one e-poster presentation, and eight poster presentations, highlighting the breadth of its research in respiratory and emerging infectious diseases.

COVID-19

  • Immunogenicity of JN.1- and KP.2-encoding mRNA COVID-19 vaccines against JN.1 SARS-CoV-2 sublineages in adult participants - Oral Presentation
    Presenter: Frances Priddy
    Session: Advances in vaccine effectiveness for viral respiratory infections
    Date: April 12 | Time & Location: 11:00 (Hall 9)

  • Relative vaccine efficacy of a SARS-CoV-2 spike receptor-binding and N-terminal domain COVID-19 vaccine versus mRNA-1273: subgroup analyses - Oral Presentation
    Presenter: Spyros Chalkias
    Session: Vaccines and prophylaxis against respiratory viral infections
    Date: April 13 | Time & Location: 11:00 (Hall 9)

  • Clinical evaluation of a SARS-CoV-2 spike receptor-binding and N-terminal domain COVID-19 vaccine - Poster Presentation
    Presenter: Spyros Chalkias
    Session: COVID-19
    Date: April 12 | Time & Location: 12:00 (Poster Hall)

  • Immunogenicity and safety of a SARS-CoV-2 N-terminal domain and receptor-binding domain monovalent XBB.1.5 vaccine in Japanese participants aged ≥12 years - Poster Presentation
    Presenter: Christina Grassi
    Session: COVID-19
    Date: April 12 | Time & Location: 12:00 (Poster Hall)

RSV

  • Six-month Immunogenicity of mRNA-1345 RSV Vaccine in Adults Aged ≥60 Years - E-Poster Presentation
    Presenter: Mihir Desai
    Session: On the frontiers of vaccine-driven prevention
    Date: April 12 | Time & Location: 08:30 (Arena 1)

  • Safety and immunogenicity of mRNA-1345 revaccination at 24 months in adults ≥60 years - Poster Presentation
    Presenter: Mihir Desai
    Session: Clinical Trials
    Date: April 15 | Time & Location: 12:00 (Poster Hall)

  • Burden of chronic medical conditions that are risk factors for severe RSV among adults aged 18-59 years in the United States - Poster Presentation
    Presenter: Clarisse Demont
    Session: Influenza and respiratory viruses
    Date: April 12 | Time & Location: 12:00 (Poster Hall)

  • Association of virology swab positivity in adults aged ≥40 years with Computerized Medical Record Reported Acute Respiratory Infection (ARI) Subgroups: Observational Study of ARI (ObservatARI) - Poster Presentation
    Presenter: Simon De Lusignan
    Session: Influenza and respiratory viruses
    Date: April 12 | Time & Location: 12:00 (Poster Hall)

Mpox

  • Safety and immunogenicity of mRNA mpox vaccine candidate mRNA-1769: Interim analysis results from a Phase 1/2 Trial - Oral Presentation
    Presenter: Hiwot Hiruy
    Session: Novel vaccines in clinical development
    Date: April 14 | Time & Location: 17:30 (Hall 3)

Cytomegalovirus

  • Long-term safety and immunogenicity of cytomegalovirus mRNA-1647 vaccine in healthy adults: 36-month results from a phase 2 extension trial - Poster Presentation
    Presenter: Ben Lorenz
    Session: Clinical Trials
    Date: April 15 | Time & Location: 12:00 (Poster Hall)

Influenza

  • Six-month persistence and safety of mRNA-based influenza or multicomponent influenza/COVID-19 vaccines versus licensed comparators in adults aged ≥18 years - Poster Presentation
    Presenter: Mieke Soens
    Session: Influenza and respiratory viruses
    Date: April 12 | Time & Location: 12:00 (Poster Hall)

Norovirus

  • Incidence and severity of sporadic, medically attended norovirus infection in the United States, 2023-2024 - Poster Presentation
    Presenter: Mark A. Schmidt
    Session: Viral epidemiology - general, prevalence studies, molecular and genomic epidemiology
    Date: April 12 | Time & Location: 12:00 (Poster Hall)

About Moderna

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.

Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the potential for Moderna's vaccine candidates to alleviate disease outcomes. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release.

Moderna Contacts

Media:
Luke Mircea-Willats
Senior Director, International Communications
Luke.Mirceawillats@modernatx.com

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
Lavina.Talukdar@modernatx.com

SOURCE: Moderna Inc.



View the original press release on ACCESS Newswire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.